Madison Austin
Medical · del City, OKNPI 1962097675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 396 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,891, 2.1 times the $888 reported in 2021. Among medical clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Dexcom, Inc.$730
- Xeris Pharmaceuticals, Inc.$597
- Insulet Corporation$489
- Sanofi-aventis U.S. LLC$465
- Novo Nordisk$456
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,32399%
- Gifts$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 75 | $1,338 |
| Dexcom, Inc. | 41 | $730 |
| Xeris Pharmaceuticals, Inc. | 32 | $597 |
| Insulet Corporation | 24 | $489 |
| Sanofi-aventis U.S. LLC | 22 | $465 |
| Novo Nordisk | 29 | $456 |
| Boehringer Ingelheim | 22 | $387 |
| Corcept Therapeutics | 23 | $386 |
| Tandem Diabetes Care, Inc. | 15 | $354 |
| Merck | 13 | $229 |
| AstraZeneca | 14 | $228 |
| Mannkind Corporation | 8 | $197 |
| AbbVie | 9 | $191 |
| Sequel Med Tech, LLC | 8 | $161 |
| Ascensia Diabetes Care US Inc. | 7 | $148 |
| Nevro Corp. | 6 | $130 |
| Exact Sciences | 8 | $127 |
| Bayer | 6 | $108 |
| BETA Bionics, Inc. | 5 | $107 |
| Abbott | 3 | $69 |
| Antares Pharma, Inc. | 4 | $68 |
| Amgen | 4 | $68 |
| Medtronic | 3 | $52 |
| GSK | 3 | $46 |
| Cequr Corporation | 2 | $40 |
| Sandoz | 1 | $27 |
| Radius Health, Inc. | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $14 |
How this compares
$7,365 in reported general payments places this provider in the 90th percentile of 370 medical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 183 | $288,932 |
| MounjaroTirzepatide | 109 | $167,199 |
| JardianceEmpagliflozin | 92 | $109,759 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $87,925 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $82,599 |
| TrulicityDulaglutide | 47 | $67,710 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $65,238 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $64,841 |
| FarxigaDapagliflozin Propanediol | 57 | $56,188 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $28,835 |
| JanuviaSitagliptin Phosphate | 26 | $27,634 |
| RybelsusSemaglutide | 15 | $24,005 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $21,371 |
| Humalog Kwikpen U-100Insulin Lispro | 46 | $20,636 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $16,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $456 | $312,936198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,338 | $234,910156 claims |
| Boehringer IngelheimJardiance | $387 | $109,75992 claims |
| AstraZenecaFarxiga | $228 | $56,18857 claims |
| MerckJanuvia | $229 | $27,63426 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $465 | $21,37113 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $2,433202 claims |
| AbbVieSynthroid | $191 | $79920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 medical providers in Oklahoma.
Other medical in del City
- Mebin ThomasOklahoma City$323K
- Kelle ChristiansonMidwest City$117K
- Kristine MurrowOklahoma City$81K
- Matthew DohlmanTulsa$39K
- Katelyn PuryearOklahoma City$22K
- Tara LinvilleTulsa$19K
- Debra OdomTulsa$17K
- Donna BowersTuttle$16K
- Kelly WalworthOklahoma City$15K
- Jere ClaunchOklahoma City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.